816 related articles for article (PubMed ID: 29330207)
21. Application of circulating tumor DNA for dynamic monitoring of advanced non-small cell lung cancer treatment response: An open-label, multicenter, prospective, observational study protocol.
Gao Z; Shang Y; Wang X; Ma Y; Yang F; Wang J; Chen K; Zhang Y
Thorac Cancer; 2019 May; 10(5):1310-1315. PubMed ID: 30980496
[TBL] [Abstract][Full Text] [Related]
22. Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Vega DM; Nishimura KK; Zariffa N; Thompson JC; Hoering A; Cilento V; Rosenthal A; Anagnostou V; Baden J; Beaver JA; Chaudhuri AA; Chudova D; Fine AD; Fiore J; Hodge R; Hodgson D; Hunkapiller N; Klass DM; Kobie J; Peña C; Pennello G; Peterman N; Philip R; Quinn KJ; Raben D; Rosner GL; Sausen M; Tezcan A; Xia Q; Yi J; Young AG; Stewart MD; Carpenter EL; Aggarwal C; Allen J
JCO Precis Oncol; 2022 Aug; 6():e2100372. PubMed ID: 35952319
[TBL] [Abstract][Full Text] [Related]
23. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers.
Parikh AR; Mojtahed A; Schneider JL; Kanter K; Van Seventer EE; Fetter IJ; Thabet A; Fish MG; Teshome B; Fosbenner K; Nadres B; Shahzade HA; Allen JN; Blaszkowsky LS; Ryan DP; Giantonio B; Goyal L; Nipp RD; Roeland E; Weekes CD; Wo JY; Zhu AX; Dias-Santagata D; Iafrate AJ; Lennerz JK; Hong TS; Siravegna G; Horick N; Clark JW; Corcoran RB
Clin Cancer Res; 2020 Apr; 26(8):1877-1885. PubMed ID: 31941831
[TBL] [Abstract][Full Text] [Related]
24. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy.
Hwang M; Canzoniero JV; Rosner S; Zhang G; White JR; Belcaid Z; Cherry C; Balan A; Pereira G; Curry A; Niknafs N; Zhang J; Smith KN; Sivapalan L; Chaft JE; Reuss JE; Marrone K; Murray JC; Li QK; Lam V; Levy BP; Hann C; Velculescu VE; Brahmer JR; Forde PM; Seiwert T; Anagnostou V
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688557
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.
Fang W; Ma Y; Yin JC; Hong S; Zhou H; Wang A; Wang F; Bao H; Wu X; Yang Y; Huang Y; Zhao H; Shao YW; Zhang L
Clin Cancer Res; 2019 Aug; 25(16):5015-5026. PubMed ID: 31085721
[TBL] [Abstract][Full Text] [Related]
26. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
[TBL] [Abstract][Full Text] [Related]
27. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
28. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
29. Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors.
Hu Y; Narayan A; Xu Y; Wolfe J; Vu D; Trinh T; Kantak C; Ivy SP; Eder JP; Deng Y; LoRusso P; Kim JW; Patel AA
JCO Precis Oncol; 2024 Feb; 8():e2300289. PubMed ID: 38412387
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
Kim JH; Kim HS; Kim BJ
Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
[TBL] [Abstract][Full Text] [Related]
31. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
[TBL] [Abstract][Full Text] [Related]
33. Plasma circulating tumor DNA unveils the efficacy of PD-1 inhibitors and chemotherapy in advanced gastric cancer.
Jiang R; Cheng X; Li P; Meng E; Wu X; Wu H
Sci Rep; 2024 Jun; 14(1):14027. PubMed ID: 38890392
[TBL] [Abstract][Full Text] [Related]
34. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.
Khagi Y; Goodman AM; Daniels GA; Patel SP; Sacco AG; Randall JM; Bazhenova LA; Kurzrock R
Clin Cancer Res; 2017 Oct; 23(19):5729-5736. PubMed ID: 28972084
[No Abstract] [Full Text] [Related]
35. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.
Cabel L; Riva F; Servois V; Livartowski A; Daniel C; Rampanou A; Lantz O; Romano E; Milder M; Buecher B; Piperno-Neumann S; Bernard V; Baulande S; Bieche I; Pierga JY; Proudhon C; Bidard FC
Ann Oncol; 2017 Aug; 28(8):1996-2001. PubMed ID: 28459943
[TBL] [Abstract][Full Text] [Related]
36. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.
Imamura F; Uchida J; Kukita Y; Kumagai T; Nishino K; Inoue T; Kimura M; Oba S; Kato K
Lung Cancer; 2016 Apr; 94():68-73. PubMed ID: 26973209
[TBL] [Abstract][Full Text] [Related]
37. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
Lee JH; Long GV; Boyd S; Lo S; Menzies AM; Tembe V; Guminski A; Jakrot V; Scolyer RA; Mann GJ; Kefford RF; Carlino MS; Rizos H
Ann Oncol; 2017 May; 28(5):1130-1136. PubMed ID: 28327969
[TBL] [Abstract][Full Text] [Related]
38. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
39. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.
Cabel L; Proudhon C; Romano E; Girard N; Lantz O; Stern MH; Pierga JY; Bidard FC
Nat Rev Clin Oncol; 2018 Oct; 15(10):639-650. PubMed ID: 30050094
[TBL] [Abstract][Full Text] [Related]
40. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer.
Wang Y; Zhao C; Chang L; Jia R; Liu R; Zhang Y; Gao X; Li J; Chen R; Xia X; Bulbul A; Husain H; Guan Y; Yi X; Xu J
EBioMedicine; 2019 May; 43():261-269. PubMed ID: 31031019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]